Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. I… Read more
Virbac SA - Asset Resilience Ratio
Virbac SA (VRBCF) has an Asset Resilience Ratio of 0.10% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2023)
This chart shows how Virbac SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Virbac SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.78 Million | 0.1% |
| Total Liquid Assets | $1.78 Million | 0.10% |
Asset Resilience Insights
- Limited Liquidity: Virbac SA maintains only 0.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Virbac SA Industry Peers by Asset Resilience Ratio
Compare Virbac SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
PINK:NVSEF |
Drug Manufacturers - General | 0.13% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 7.18% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
Annual Asset Resilience Ratio for Virbac SA (2009–2023)
The table below shows the annual Asset Resilience Ratio data for Virbac SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $-43.00K | $1.46 Billion | +0.44pp |
| 2022-12-31 | -0.45% | $-5.94 Million | $1.33 Billion | +0.01pp |
| 2021-12-31 | -0.46% | $-5.52 Million | $1.20 Billion | -0.23pp |
| 2020-12-31 | -0.23% | $-2.60 Million | $1.11 Billion | -0.26pp |
| 2019-12-31 | 0.03% | $342.00K | $1.32 Billion | +0.87pp |
| 2018-12-31 | -0.84% | $-10.73 Million | $1.27 Billion | -0.95pp |
| 2017-12-31 | 0.11% | $1.34 Million | $1.28 Billion | +0.85pp |
| 2016-12-31 | -0.74% | $-10.53 Million | $1.42 Billion | +0.10pp |
| 2015-12-31 | -0.84% | $-12.07 Million | $1.43 Billion | +0.19pp |
| 2014-12-31 | -1.03% | $-13.67 Million | $1.33 Billion | -1.11pp |
| 2013-12-31 | 0.08% | $735.00K | $896.23 Million | -0.11pp |
| 2011-12-31 | 0.19% | $1.14 Million | $588.63 Million | -0.01pp |
| 2010-12-31 | 0.20% | $1.08 Million | $533.75 Million | -17.62pp |
| 2009-12-31 | 17.83% | $77.45 Million | $434.47 Million | -- |